Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer’s disease and related dementias

Researchers Test Strategies to Prevent Alzheimer Disease

(2014) M. J. Friedrich   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Chasing the “White Whale” of Alzheimer's

(2014) Daniel R. George et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

The Metalloprotease Meprin β Generates Amino Terminal-truncated Amyloid β Peptide Species

(2012) Jessica Bien et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β

(2012) Justin M. Nussbaum et al.   NATURE

Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

(2012) Jeffrey L. Frost et al.   Neurodegenerative Diseases

Statistical Association and Causation

(2011) Charles H. Hennekens   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

(2011) Sadim Jawhar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Alzheimer's failure raises questions about disease-modifying strategies

(2010) Andy Extance   NATURE REVIEWS DRUG DISCOVERY

Decreased Clearance of CNS  -Amyloid in Alzheimer's Disease

(2010) K. G. Mawuenyega et al.   SCIENCE

Glutaminyl Cyclases Display Significant Catalytic Proficiency for Glutamyl Substrates

(2009) Franziska Seifert et al.   BIOCHEMISTRY

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

(2008) Stephan Schilling et al.   NATURE MEDICINE